Dengue is one of the most worrisome diseases throughout a great extension of the planet.
This infectious diseaseis caused by a virus, transmitted by a mosquito, and is guilty of dangerous hemorrhagic fevers feared throughout much of the southern hemisphere.
Years ago it began to distribute Dengvaxia, a vaccine that seemed effective, but only in patients between 9 and 16 years old. Interestingly, after a while, those who were not in that age range not only were not protected, but could catch more seriously. Therefore, it is necessary to obtain a beneficial vaccine for patients of all ages, something that could soon become a reality thanks to the experimental vaccine, recently developed by a group of American researchers who has published his results in the magazine Science Translational Medicine.
What is dengue?
Dengue is a characteristic disease of the tropical climate, Which affects 400 million people a year, reaching an average of 25,000 deaths annually.
Although in many cases it can start being asymptomatic, is characterized by strong headaches and jointsinflammation in the lymph nodes and skin rash. In addition, less frequently there may also be a drastic decrease in the number of platelets of the patient, who ends up causing all kinds of hemorrhages, accompanied by fever, vomiting and liver and kidney complications.
As I said at the beginning, the only vaccine currently available is not entirely effective, so those countries where it is a public health problem focus their efforts on the elimination of Aedes aegypti, the mosquito that acts as principal disease vector.
The first steps in the most effective dengue vaccine
To check the effectiveness of this vaccine, which they have called TV003, we proceeded to inject her 20 patients, while 21 others were administered a placebo. Then after giving your consent, they were all infected with a highly attenuated strain of the virus, to check if they had been protected.
As expected, almost all the patients who received placebo, specifically 80%, showed the typical symptoms of disease while the 100% those who had been vaccinated remained healthy and only a few had some minor side effects.
Proud of the results, these scientists have just begun the second stage of the research, which will take place in Brazil, the results of which will be published in 2018. Hopefully they will be as favorable as those they have had so far.